Progress of bispecific antibody in the treatment of non-small cell lung cancer

VernacularTitle:双特异性抗体在非小细胞肺癌治疗中的进展
Author: Xueqian QIN ¹ ; Hongyu YANG ; Zhen WANG ; Mengchao WANG ; Xin ZHANG
Author Information

1. 天津中医药大学第一附属医院肿瘤科，天津　300380
Keywords: Carcinoma, non-small-cell lung; Antibodies, bispecific; Therapy
From: Journal of International Oncology 2023;50(9):558-563
CountryChina
Language:Chinese
Abstract: Bispecific antibody (BsAb) is a new type of highly effective anti-tumor drug that can specifically bind two antigens or epitopes simultaneously or successively. At present, evantuzumab targeting epidermal growth factor receptor (EGFR) and cMET has been approved for the treatment of EGFR ex20ins in locally advanced or metastatic non-small cell lung cancer (NSCLC) . Inhibitors targeting programmed death-ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) , programmed death-1 (PD-1) and CTLA-4, PD-L1 and transforming growth factor-β, PD-1 and vascular endothelial growth factor are applied to NSCLC. The treatment of NSCLC is underway, showing good safety and efficacy. Further exploring the research progress of BsAbs in the treatment of NSCLC will provide a new diagnosis and treatment idea for the clinical treatment of NSCLC.